After two other liver disease projects fade into the background Ionis delays the antisense asset AKCEA-ANGPTL3-LRx by a year.
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
Intercept’s Regenerate trial in Nash, one of the hottest clinical readouts of 2019, is technically a success, but toxicity casts a long shadow.
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
Galapagos will discover if filgotinib can hang on to its reputation as one of the safest Jak inhibitors in the industry, while Cara is itching for pivotal trial success…
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
The failure of the Stellar-4 study of selonsertib is a big blow for Gilead, but has not dented enthusiasm for other Nash players.
Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.